Who
Marc Grasso
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Kyverna Therapeutics; Chief Financial Officer, Alector; CFO, Cbo, Kura Oncology.
In numbers
- Trades disclosed
- 41
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $1.2M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 21 Aug 2018
- Last trade
- 13 Mar 2026
- Last filed
- 17 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Mar 2026filed 17 Mar 2026 | KYTX Kyverna TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 13 Mar 2026filed 17 Mar 2026 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 13 Mar 2026filed 17 Mar 2026 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 13 Mar 2026filed 17 Mar 2026 | KYTX Kyverna TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 30 Jun 2025filed 1 Jul 2025 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 2 Jun 2025filed 4 Jun 2025 | ALEC AlectorBiotechnology | SEC FORM 4 Sold | $22K16,488 at $1.34 | filing |
| 3 Mar 2025filed 5 Mar 2025 | ALEC AlectorBiotechnology | SEC FORM 4 Sold | $27K18,091 at $1.47 | filing |
| 2 Dec 2024filed 3 Dec 2024 | ALEC AlectorBiotechnology | SEC FORM 4 Sold | $42K16,489 at $2.52 | filing |
| 1 Oct 2024filed 2 Oct 2024 | ALEC AlectorBiotechnology | SEC FORM 4 Code A | —216,400 at $0.00 | filing |
| 3 Sep 2024filed 4 Sep 2024 | ALEC AlectorBiotechnology | SEC FORM 4 Sold | $36K7,297 at $4.88 | filing |
| 3 Jun 2024filed 4 Jun 2024 | ALEC AlectorBiotechnology | SEC FORM 4 Sold | $33K6,920 at $4.80 | filing |
| 4 Mar 2024filed 5 Mar 2024 | ALEC AlectorBiotechnology | SEC FORM 4 Sold | $40K5,716 at $6.92 | filing |
| 4 Dec 2023filed 6 Dec 2023 | ALEC AlectorBiotechnology | SEC FORM 4 Sold | $25K4,574 at $5.56 | filing |
| 1 Oct 2023filed 3 Oct 2023 | ALEC Alectoroption or derivative · Biotechnology | SEC FORM 4 Code A | —41,000 at $0.00 | filing |
| 1 Oct 2023filed 3 Oct 2023 | ALEC AlectorBiotechnology | SEC FORM 4 Code A | —123,000 at $0.00 | filing |
| 5 Sep 2023filed 6 Sep 2023 | ALEC AlectorBiotechnology | SEC FORM 4 Sold | $5,7821,114 at $5.19 | filing |
| 2 Jun 2023filed 5 Jun 2023 | ALEC AlectorBiotechnology | SEC FORM 4 Sold | $7,2451,050 at $6.90 | filing |
| 2 Mar 2023filed 3 Mar 2023 | ALEC AlectorBiotechnology | SEC FORM 4 Sold | $11K1,291 at $8.32 | filing |
| 1 Oct 2022filed 4 Oct 2022 | ALEC Alectoroption or derivative · Biotechnology | SEC FORM 4 Code A | —23,801 at $0.00 | filing |
| 1 Oct 2022filed 4 Oct 2022 | ALEC AlectorBiotechnology | SEC FORM 4 Code A | —35,702 at $0.00 | filing |
News
Cyllene Therapeutics Appoints Seasoned Biotech Executive Dr Marc Grasso as Chief Financial Officerfinanznachrichten.de · 17 Sep 2026Alector (NASDAQ: ALEC) prices shares at a 7.3% premium in stock saleALEC · dailypolitical.com · 18 Oct 2026Alector Maps Brain-Delivery Pipeline for Alzheimer's, Parkinson's TherapiesALEC · dailypolitical.com · 13 Oct 2026Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in DiabetesKURA · manilatimes.net · 13 Oct 2026Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled PipelineALEC · manilatimes.net · 7 Oct 2026Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in DiabetesKURA · manilatimes.net · 7 Oct 2026
1 headline in the last 90 days name Marc Grasso; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.